3031 Research Drive
Richmond, CA 94806
Phone: 510-222-9700
www.onyx-pharm.com

Hollings C. Renton, chairman and CEO
NASDAQ:ONXX

Overview

Founded in 1992, Onyx Pharmaceuticals intends to change the way cancer is treated by developing innovative treatments on therapeutic adenoviruses to multiply in malignant cells and destroy them. The company’s ONYX-15 is in Phase III clinical development for the treatment of head and neck cancer and earlier-stage development for the treatment of pancreatic, ovarian, colorectal and lung cancers.

Onyx also is also developing pRB-selective viruses, which, like ONYX-15, are designed to kill cancer cells while sparing normal cells. Onyx is developing a number of technologies that complement the selectively replicating viruses, including arming viruses with anticancer genes (Armed Therapeutic Viruses, or ATV), which would be able to selectively produce and amplify the concentration of anticancer genes within the tumor. Onyx also is working with Pfizer Inc. and Bayer AG to identify and develop small-molecule therapeutic compounds for a number of cancers.

Partners

Onyx has collaborations with Pfizer Inc., Warner-Lambert Co. and Bayer AG to identify and develop small-molecule therapeutic compounds for a number of cancers. XOMA Ltd., of Cambridge, Mass., is developing and manufacturing ONYX-15 for Onyx. In November 2001, Syrrx Inc., of San Diego, acquired some of Onyx's small-molecule assets in exchange for equity, milestone and royalty payments to Onyx.